<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033656</url>
  </required_header>
  <id_info>
    <org_study_id>NordicAOSD05</org_study_id>
    <secondary_id>2005-003173-24</secondary_id>
    <nct_id>NCT01033656</nct_id>
  </id_info>
  <brief_title>Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study</brief_title>
  <acronym>NordicAOSD05</acronym>
  <official_title>An Open, Randomized Study Treating Refractory Adult-onset Still's Disease With Interleukin-1 Receptor Antagonist Anakinra (Kineret), Compared to an Established, Single Anti-rheumatic Drug Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jyväskylä Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Satakunta Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Umeå</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Helsinki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open, randomized, parallel-group, comparative, multicentre study. Patients on&#xD;
      corticosteroids (plus conventional therapy) will be randomized to receive anakinra&#xD;
      (Kineret®), or one of the following: methotrexate, azathioprine, leflunomide, cyclosporin A&#xD;
      or sulphasalazine. Patients enter the study if considered refractory to corticosteroids&#xD;
      (prednisolone equivalent ≥10 mg/day) at the time of randomization.&#xD;
&#xD;
      The randomized phase of the study will be followed by an open-label extension (OLE) phase, to&#xD;
      follow-up drug survival, efficacy, tolerability and disease-related parameters of long-term&#xD;
      treatment with anakinra or one of the study DMARDs or a combination of study drugs for&#xD;
      additional 28 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Product: Kineret (anakinra) Comparative agents: Methotrexate or azathioprine or leflunomide&#xD;
      or cyclosporin A or sulphasalazine Protocol title: An open, randomized study treating&#xD;
      refractory adult-onset Still's disease with IL-1ra anakinra (Kineret, compared to an&#xD;
      established, single anti-rheumatic treatment Target Disease: Adult-onset Still's disease&#xD;
      Patients: 23 patients diagnosed with AOSD, living in the four Nordic countries.&#xD;
&#xD;
      Study Objectives: To follow the changes in clinical status and disease activity in patients&#xD;
      receiving anakinra, compared to those treated with an established DMARD, in addition to&#xD;
      corticosteroids in patients with refractory AOSD. To compare the changes in disease-related&#xD;
      parameters (global health, patient's assessment on disease, laboratory values) in the two&#xD;
      randomized groups. To assess the safety of anakinra in AOSD. To follow-up drug survival,&#xD;
      efficacy, tolerability and disease-related parameters of long-term treatment in AOSD (open&#xD;
      phase).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients reaching remission of the disease, after eight weeks of the randomized study treatment (Remission: afebrile and normalization of acute phase reactants)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Adult-Onset Still's Disease</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental drug of study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>comparators:methotrexate, azathioprine, leflunomide or supfasalazine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anakinra</intervention_name>
    <description>100 mg subcutaneous injection daily</description>
    <arm_group_label>Anakinra</arm_group_label>
    <other_name>Interleukin-1 receptor antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>comparators</intervention_name>
    <description>po drugs, comparators</description>
    <arm_group_label>comparator</arm_group_label>
    <other_name>methotrexate, azathioprine, leflunomide, sufalalazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be diagnosed with AOSD according to preliminary classification by Yamaguchi&#xD;
             (1992).&#xD;
&#xD;
          -  Other diseases with similar symptoms must be excluded. Has been exposed to a&#xD;
             corticosteroid for ≥2 months prior to randomization for AOSD.&#xD;
&#xD;
          -  Needs a prednisolone dose ≥10 mg/day or equivalent, yet unacceptable disease activity&#xD;
             determined by the investigator.&#xD;
&#xD;
          -  Anti-TNF agents must be discontinued 4 to 8 weeks prior to commencing study&#xD;
             medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of corticosteroids (prednisolone equivalent &lt;10 mg/day.&#xD;
&#xD;
          -  History of recurrent or chronic infection, including:&#xD;
&#xD;
               -  tuberculosis&#xD;
&#xD;
               -  any malignancy&#xD;
&#xD;
               -  any other major chronic inflammatory disease syndrome&#xD;
&#xD;
               -  drug or alcohol abuse&#xD;
&#xD;
               -  known positivity for hepatitis B, C or HIV.&#xD;
&#xD;
          -  Use of anti-TNF agents during ≤4 weeks (etanercept) or≤8 weeks (infliximab or&#xD;
             adalimumab) prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan C Nordstrom, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Hospital, Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ann Kataja Knight</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Helsinki</investigator_affiliation>
    <investigator_full_name>Dan Nordstrom</investigator_full_name>
    <investigator_title>ass.prof</investigator_title>
  </responsible_party>
  <keyword>adult-onset Still's disease</keyword>
  <keyword>anakinra</keyword>
  <keyword>prednisolone</keyword>
  <keyword>disease-modifying antirheumatic drug</keyword>
  <keyword>methotrexate</keyword>
  <keyword>efficacy</keyword>
  <keyword>patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Still's Disease, Adult-Onset</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

